Evolent Health, Inc (NYSE:EVH - Get Free Report)'s stock price was up 5.4% during mid-day trading on Monday . The stock traded as high as $9.85 and last traded at $9.75. Approximately 3,240,371 shares were traded during mid-day trading, an increase of 34% from the average daily volume of 2,414,981 shares. The stock had previously closed at $9.25.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on EVH shares. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a research note on Tuesday, May 13th. Truist Financial cut their target price on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. JMP Securities restated a "market outperform" rating and set a $13.00 price objective on shares of Evolent Health in a research report on Friday. JPMorgan Chase & Co. cut their price objective on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research report on Monday, March 10th. Finally, UBS Group raised their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $17.79.
Get Our Latest Stock Analysis on EVH
Evolent Health Price Performance
The company's fifty day moving average price is $8.85 and its 200 day moving average price is $9.80. The company has a market capitalization of $1.25 billion, a P/E ratio of -8.64 and a beta of 0.87. The company has a quick ratio of 0.98, a current ratio of 0.98 and a debt-to-equity ratio of 0.69.
Evolent Health (NYSE:EVH - Get Free Report) last announced its earnings results on Thursday, May 8th. The technology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.02). The business had revenue of $483.65 million for the quarter, compared to the consensus estimate of $460.15 million. Evolent Health had a positive return on equity of 3.64% and a negative net margin of 4.54%. The firm's revenue for the quarter was down 24.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.34 earnings per share. As a group, sell-side analysts forecast that Evolent Health, Inc will post 0.08 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise bought a new position in Evolent Health in the first quarter valued at approximately $25,000. Pilgrim Partners Asia Pte Ltd bought a new position in Evolent Health in the fourth quarter valued at approximately $26,000. AlphaQuest LLC increased its stake in Evolent Health by 21,650.0% in the fourth quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after acquiring an additional 3,031 shares during the last quarter. Strs Ohio bought a new position in Evolent Health in the first quarter valued at approximately $47,000. Finally, US Bancorp DE increased its stake in Evolent Health by 291.0% in the first quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock valued at $49,000 after acquiring an additional 3,835 shares during the last quarter.
About Evolent Health
(
Get Free Report)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Featured Articles
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
